A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of 2 mg/kg Bolus Plus 24-hour 0.5 mg/kg/hr Infusion Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass

  • Ramaiah, Chandrashekhar (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date8/1/04 → 7/31/06